High grade glioma, Metastatic brain tumor, Primary Central Nerve System Lymphoma
Conditions
Interventions
One vial of fluciclovine injection is administered intravenously, and imaging is started 10 to 50 minutes later using positron emission tomography. Imaging is performed up to 60 minutes after administ
Sponsors
Tanaka Shota
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) 18 years old or older 2) Patients suspected of having a malignant brain tumor based on MRI examination, and whose differential diagnosis includes malignant glioma, including glioblastoma 3) No restrictions on previous cancer history 4) Patients who have given written consent of their own free will (or a substitute decision-maker if aphasia or other condition makes it difficult for the patient to sign) after being fully informed of the study and fully understanding it
Exclusion criteria
Exclusion criteria: 1) Patients with tumorous lesions that show marked midline deviation 2) Patients with tumorous lesions presenting with severe hydrocephalus 3) Patients with a KPS score of 50 or less 4) Patients who are judged to be unable to safely undergo the examination due to severe aphasia or higher brain dysfunction 5) Patients who are judged to be unsuitable as research subjects by the principal investigator or subinvestigatorse for inclusion in the study by the principal investigator or sub-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The correlation between the quantitative evaluation of flucyclovine accumulation in flucyclovine PET and histological findings will be investigated. The quantitative evaluation of flucyclovine will be obtained and evaluated as a standardized uptake value (SUV) value. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Correlation between the fluorescent positive sites of 5-aminolevulinic acid, an intraoperative fluorescent probe used in surgery for cases suspected of having malignant glioma, and the uptake sites of fluciclovine PET. 2) Evaluation of the difference in fluciclovine accumulation between malignant glioma and tumors that require differentiation, and the ability to differentiate between them. | — |
Contacts
Public ContactShuichiro Hirano
Okayama University Hospital
Outcome results
None listed